Login
Business
Entertainment
World
Health
Environment
Lifestyle
National
Science
Sports
World
Movies
Web Series
Technology
Cricket
Coronavirus
Auto
Ajab Ghazab
Finance
India
International
Religious
Politics
Home Articles UPMC Hillman Cancer Center
Cancer fighting nanoparticles deliver a chemotherapy drug, immunotherapy: Study \
6 min read
\
\

Cancer fighting nanoparticles deliver a chemotherapy drug, immunotherapy: Study

 25-Nov-2022
Researchers found and developed nanoparticles that simultaneously carry chemotherapy and a new immunotherapy. Chemotherapy is a pillar of cancer treatment, but residual cancer cells can persist and cause tumor relapse.
25-Nov-2022 Health
\
Research: Innovative cancer chemoimmunotherapy provided by novel nanoparticles \
6 min read
\
\

Research: Innovative cancer chemoimmunotherapy provided by novel nanoparticles

 25-Nov-2022
Researchers from the University of Pittsburgh have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy.
25-Nov-2022 Science
\
Study finds importance of malaria drug in treating neck cancers \
4 min read
\
\

Study finds importance of malaria drug in treating neck cancers

 20-Mar-2022
Washington [US], March 20 (ANI): Do you know malaria drugs work against some cancers? According to a new study, the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumour-killing effects of cisplatin in animal models.
20-Mar-2022 Science
\
Malaria drug could combat chemotherapy-resistant head, neck cancers: Study \
4 min read
\
\

Malaria drug could combat chemotherapy-resistant head, neck cancers: Study

 15-Mar-2022
Washington [US], March 15 (ANI): A new study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumour-killing effects of cisplatin in animal models.
15-Mar-2022 Health
\
Patients with high-risk local melanomas benefit from immunotherapy drug: Study \
5 min read
\
\

Patients with high-risk local melanomas benefit from immunotherapy drug: Study

 20-Sep-2021
Pennsylvania [US], September 20 (ANI): According to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center, immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma.
20-Sep-2021 Science
\